IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A biphasic injectable composition comprising:

biocompatible micronized textured polyethylene particles having a size greater than sixty microns, and

a carrier.

~~solid polymer particles, wherein the solid polymer particles are mechanically stable and are mechanically stable and are suspended in a liquid carrier substrate.~~

2. (Canceled)

3. (Canceled)

4. (Currently Amended) The composition of Claim 1, wherein the ~~liquid~~ carrier ~~substrate phase~~ is selected from polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.

5. (Canceled)

6. (Canceled)

7. (Currently Amended) The composition of Claim 1, wherein the ~~liquid~~ carrier ~~substrate phase~~ is polyvinylpyrrolidone.

8. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

9. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Canceled)

13. (Currently Amended) The composition of Claim 1 wherein the ~~e-PTFE~~ biocompatible micronized textured polyethylene and the ~~PVP~~ carrier are combined at a ratio of approximately 3:2 ~~polyvinylpyrrolidone~~ carrier to ~~e-PTFE~~ biocompatible micronized textured polyethylene by weight.

14. (Canceled)

15. (Withdrawn) A method for tissue augmentation comprising:

injecting a biphasic injectable composition comprising:

solid polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.

16. (Withdrawn) The method of Claim 15, wherein the mechanically stable solid polymer particles are made from micronized expanded polytetrafluoroethelene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly e-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.

17. (Withdrawn) The method of Claim 15, wherein the liquid carrier substrate is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.

18. (Withdrawn) The method of Claim 15, wherein injecting comprises:

inserting a delivery apparatus containing the biphasic injectable composition into the injection site.

19. (Withdrawn) The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.

20. (New) The composition of Claim 1, wherein the textured particles have a size greater than eighty microns.

21. (New) The composition of Claim 1, wherein the textured particles have a size greater than one-hundred microns.

22. (New) A biphasic injectable composition comprising:

biocompatible micronized textured polyethylene particles having a size of greater than sixty microns; and

a carrier comprising polyvinylpyrrolidone.

23. (New) The composition of Claim 22 wherein the biocompatible micronized textured polyethylene and the carrier are combined at a ratio of approximately 3:2 carrier to biocompatible micronized textured polyethylene by weight.

24. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

25. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

26. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

27. (New) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.

28. (New) The composition of Claim 22, wherein the textured particles have a size greater than eighty microns.

29. (New) The composition of Claim 22, wherein the textured particles have a size greater than one-hundred microns.